Published in Medical Letter on the CDC and FDA, September 18th, 2005
"The IF8100 is built on the same platform as our existing IF8000 model for treating muscle spasms and for pain management and recovery following orthopedic surgery," said Zynex president and chief executive officer Thomas Sandgaard.
Zynex is in the process of preparing the IF8100 for submission to the U.S. Food and Drug Administration (FDA) for approval.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.